Biogen Inc. (BIIB)
Company Info
US09062X1037
09062X103
Sep 16, 1991
Highlights
$18.40B
$10.12
12.41
6.24
$9.70B
$7.15B
$2.15B
$110.04 - $238.00
$171.85
2.81%
1.77
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Biogen Inc. (BIIB) returned -17.87% year-to-date (YTD) and -45.53% over the past 12 months. Over the past 10 years, BIIB returned -10.99% annually, underperforming the S&P 500 benchmark at 10.89%.
BIIB
-17.87%
5.88%
-21.50%
-45.53%
-16.90%
-10.99%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.12%
10.89%
Monthly Returns
The table below presents the monthly returns of BIIB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -5.88% | -2.38% | -2.60% | -11.52% | 3.72% | -17.87% | |||||||
| 2024 | -4.68% | -12.03% | -0.63% | -0.38% | 4.71% | 3.06% | -8.03% | -3.96% | -5.33% | -10.24% | -7.68% | -4.80% | -40.91% |
| 2023 | 5.05% | -7.23% | 3.03% | 9.42% | -2.57% | -3.90% | -5.15% | -1.05% | -3.87% | -7.58% | -1.46% | 10.55% | -6.55% |
| 2022 | -5.80% | -6.63% | -0.19% | -1.50% | -3.59% | 1.97% | 5.45% | -9.15% | 36.66% | 6.16% | 7.67% | -9.26% | 15.42% |
| 2021 | 15.42% | -3.44% | 2.52% | -4.44% | 0.06% | 29.46% | -5.64% | 3.73% | -16.50% | -5.76% | -11.60% | 1.77% | -2.02% |
| 2020 | -9.40% | 14.71% | 2.59% | -6.18% | 3.46% | -12.88% | 2.67% | 4.71% | -1.38% | -11.14% | -4.72% | 1.95% | -17.48% |
| 2019 | 10.92% | -1.73% | -27.94% | -3.02% | -4.34% | 6.65% | 1.69% | -7.60% | 5.95% | 28.30% | 0.37% | -1.03% | -1.39% |
| 2018 | 9.18% | -16.91% | -5.25% | -0.08% | 7.44% | -1.27% | 15.20% | 5.72% | -0.05% | -13.88% | 9.68% | -9.83% | -5.54% |
| 2017 | -2.24% | 4.10% | -5.26% | -0.81% | -8.64% | 9.52% | 6.72% | 9.31% | -1.09% | -0.47% | 3.37% | -1.12% | 12.34% |
| 2016 | -10.87% | -5.00% | 0.35% | 5.64% | 5.36% | -16.54% | 19.89% | 5.42% | 2.42% | -10.49% | 4.96% | -3.57% | -7.43% |
| 2015 | 14.64% | 5.25% | 3.09% | -11.44% | 6.17% | 1.75% | -21.08% | -6.74% | -1.85% | -0.45% | -1.26% | 6.79% | -9.75% |
| 2014 | 11.83% | 8.97% | -10.22% | -6.13% | 11.23% | -1.27% | 6.05% | 2.59% | -3.57% | -2.94% | -4.17% | 10.32% | 21.42% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BIIB is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Biogen Inc. (BIIB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Biogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Biogen Inc. was 90.00%, occurring on Dec 16, 1994. Recovery took 258 trading sessions.
The current Biogen Inc. drawdown is 73.61%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90% | Oct 17, 1991 | 802 | Dec 16, 1994 | 258 | Dec 26, 1995 | 1060 |
| -76.18% | Mar 23, 2015 | 2530 | Apr 10, 2025 | — | — | — |
| -66.51% | Mar 7, 2000 | 34 | Apr 24, 2000 | 109 | Sep 27, 2000 | 143 |
| -62.59% | Dec 19, 2000 | 555 | Mar 11, 2003 | 1158 | Oct 15, 2007 | 1713 |
| -61.96% | Oct 8, 1997 | 227 | Sep 1, 1998 | 76 | Dec 18, 1998 | 303 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Biogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Biogen Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 1.9% positive surprise.
Valuation
The Valuation section provides an overview of how Biogen Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BIIB, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/E ratio of 12.4. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BIIB compared to other companies in the Drug Manufacturers - General industry. BIIB currently has a PEG ratio of 6.2. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BIIB relative to other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/S ratio of 1.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BIIB in comparison with other companies in the Drug Manufacturers - General industry. Currently, BIIB has a P/B value of 1.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |